March 26, 2025 – Fawkes Biotechnology, an innovative leader in medical diagnostics, is excited to announce the opening of its first funding round to support the development and commercialization of its groundbreaking point-of-care device for the rapid detection of concussions and mild traumatic brain injuries (mTBI). This technology promises to transform how brain injuries are diagnosed and managed, offering a fast, reliable, and accessible solution for patients, healthcare providers, and sports organizations alike.
Fawkes Biotechnology’s device is designed to deliver accurate concussion and mTBI assessments at the point of care—whether at home after a fall, on the sidelines of a sports field, in an emergency room, or at a primary care clinic. By leveraging advanced biomarker detection and analysis, the device provides results in minutes, enabling timely decision-making that can improve patient outcomes and reduce the long-term risks associated with undiagnosed brain injuries.
June 10, 2020 - Fawkes Point of Care Device Shows Positive Results in NCAA Sports Sideline Concussion Study
Copyright © Fawkes Biotechnology - All Rights Reserved.